NF1 and neurofibromatosis type 1: As we learn more about neurofibromin binding partners, tissue-specific functions and RAS-independent regulatory properties, it is likely that more precise therapeutic agents will emerge to selectively and effectively treat some of the clinical manifestations of NF1 in patients.